Results 71 to 80 of about 21,232,041 (300)

Troponin-I as a Prognostic Marker in Patients with Coronavirus Disease 2019: Insights from a Single-center Investigation

Current Medical Issues
Background: Troponin-I is conventionally correlated with myocardial injury, but its relevance in assessing the severity of coronavirus disease 2019 (COVID-19) and its implications for patient management remains an area of ongoing investigation.
Dany John, Ramesh Kawade, Abhijeet B Shelke   +2 more
doaj   +1 more source

Cardiac troponin I (CTnI) level among children with epileptic seizures

The Egyptian Heart Journal, 2014
Epilepsy is a common chronic neurological disorder in pediatric age characterized by recurrent, unprovoked seizures; these seizures are transient signs of abnormal excessive or hyper synchronous neuronal activity in the brain.
Ahmed Anwer Attia Khattab, Sameh Abdallah Abd-Elnaby, Ashrf Abd-Elraaof Dwood, Maha Attia Hagras   +3 more
doaj   +1 more source

Prognostic Value of Cardiac Troponin I and Left Ventricular Hypertrophy in Mortality of Chronic Hemodialysis Patients [PDF]

Cardiovascular events are the most common cause of death in hemodialysis patients. Cardiac biomarkers and especially Cardiac troponin I has been used as a prognostic marker in hemodialysis patients and there is some controversies about its value.
ذاکری, آناهیتا, قائمیان, ندا, حبیب زاده, شهرام, بشردوست, بهمن   +3 more
core  

Molecular mechanisms of the regulation of ATPase cycle in striated muscle [PDF]

, 2007
New data on the molecular mechanism of the regulation of ATPase cycle by troponin-tropomyosin system have been obtained in reconstructed muscle fibers by using the polarized fluorescence technique, which allowed us following the azimuthal movements of ...
Yuri S. Borovikov, Olga E. Karpicheva, Charles S. Redwood   +2 more
core  

The clinical and diagnostic performance characteristics of the high sensitivity Abbott cardiac troponin I assay

, 2015
OBJECTIVES: The aim of this study is to determine the imprecision profile, 99th percentile and diagnostic efficiency of a new high sensitivity cardiac troponin I (cTnI) assay. METHODS: Total imprecision was assessed by following CLSI protocol EP15-A.14.
Gaze, D.C., Collinson, P., Goodacre, S.
core   +1 more source

Phase II Study of Posttransplant Cyclophosphamide‐Based Graft‐Versus‐Host Disease Prophylaxis After HLA‐Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort

American Journal of Hematology, EarlyView.
ABSTRACT Posttransplant cyclophosphamide (PTCy) to prevent graft‐versus‐host disease (GVHD) improves outcomes in recipients of HLA mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (allo HCT). Outcomes of MMUD HCT using PTCy in patients requiring reduced intensity or non‐myeloablative conditioning (RIC/NMA) are not well ...
Brian C. Shaffer, Monzr M. Al Malki, Antonio Martin Jimenez Jimenez, Joseph Stanek, Stephanie Bo‐Subait, Brent R. Logan, Jianqun Kou, Erin Leckrone, Heather E. Stefanski, Stephen R. Spellman, Craig Malmberg, Medhat Askar, Rachel Cusatis, Dipenkumar Modi, Farhad Khimani, Mehdi Hamadani, Martin Maiers, Rachel Cook, Karen Ballen, Javier Bolaños‐Meade, Uttam Rao, Jordan Milner, Ramzi Abboud, Katarzyna Jamieson, George Carrum, Bhagirathbhai Dholaria, William J. Hogan, Ran Reshef, Satyajit Kosuri, Alison Loren, Karilyn Larkin, Sally Arai, Muna Qayed, Sung Won Choi, Larisa Broglie, Jeffery J. Auletta, Bronwen E. Shaw, Steven M. Devine, Mahasweta Gooptu   +38 more
wiley   +1 more source

Troponin-I release after cardiac surgery with different surgical techniques and post-operative neurological outcomes-0

, 2011
Copyright information:Taken from "Troponin-I release after cardiac surgery with different surgical techniques and post-operative neurological outcomes"McGill Journal of Medicine : MJM 2006;9(2):88-94.Published online Jan 2006PMCID:PMC2323524.Copyright ©
Akhshay Kumar Bisoi (90849), Norzeihan Jan Bappu (90847), Panangipalli Venugopal (90848), Pankaj S Mankad (90850)   +3 more
core   +1 more source

Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes, Luisa R. Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh, Jens Y. Humrich   +10 more
wiley   +1 more source

Antibody coated conductive polymer for the electrochemical immunosensing of Human Cardiac Troponin I in blood plasma

, 2021
Cardiac troponin I (cTnI) is a sensitive biomarker for cardiovascular disease (CVD). Rapid determination of cTnI concentration in blood can greatly reduce the potential of significant heart damage and heart failure.
Ayoko, GA, O'Mullane, AP, Sonar, P, Izake, EL, Gholami, MD   +4 more
core   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source